List of Excipients in Branded Drug WINLEVI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sun Pharmaceutical Industries Inc	WINLEVI	clascoterone	47335-994	ALPHA-TOCOPHEROL	2030-07-25
Sun Pharmaceutical Industries Inc	WINLEVI	clascoterone	47335-994	CETYL ALCOHOL	2030-07-25
Sun Pharmaceutical Industries Inc	WINLEVI	clascoterone	47335-994	EDETATE DISODIUM	2030-07-25
Sun Pharmaceutical Industries Inc	WINLEVI	clascoterone	47335-994	GLYCERYL MONO- AND DICAPRYLOCAPRATE	2030-07-25
Sun Pharmaceutical Industries Inc	WINLEVI	clascoterone	47335-994	MINERAL OIL	2030-07-25
Sun Pharmaceutical Industries Inc	WINLEVI	clascoterone	47335-994	POLYSORBATE 80	2030-07-25

Winlevi Excipient Strategy and Commercial Opportunities

Last updated: August 29, 2026

Winlevi is a topical clascoterone 1% cream approved by the FDA for acne vulgaris in patients 12 years and older. Its excipient strategy is commercially important because the product depends on local skin delivery, cosmetic acceptability, preservative performance, and consistent release from a semisolid vehicle. The strongest opportunities are improved dermatologic vehicles, differentiated packaging, combination products, regional manufacturing, and generic or authorized-generic development.

What is Winlevi and how does its formulation work?

Winlevi contains clascoterone, a topical androgen-receptor inhibitor. The product is applied as a cream to acne-affected skin, where clascoterone is intended to act locally. The FDA-approved product is a 1% cream supplied in a tube and indicated for patients aged 12 years and older with acne vulgaris.[1]

The formulation must balance four technical objectives:

1. Dissolve or adequately disperse clascoterone.
2. Release the drug at the skin surface and into the relevant epidermal compartments.
3. Minimize irritation, dryness, greasiness, and residue.
4. Maintain chemical and microbiological stability during shelf life.

Clascoterone is a steroidal molecule with limited water solubility. The product therefore relies on a nonaqueous or mixed solvent and emulsion system rather than a simple aqueous gel. The vehicle must support drug uniformity and reproducible topical delivery without materially increasing systemic exposure.

What excipients are used in Winlevi cream?

The FDA labeling identifies the inactive ingredients as benzyl alcohol, cetyl alcohol, citric acid monohydrate, glycerin, glyceryl stearate, isopropyl myristate, potassium sorbate, propylene glycol, purified water, stearyl alcohol, and tromethamine.[1]

Excipient	Likely formulation role	Commercial or technical relevance
Benzyl alcohol	Preservative and solvent	Can affect irritation, odor, and regulatory acceptability
Cetyl alcohol	Consistency agent and co-emulsifier	Contributes to viscosity and skin feel
Citric acid monohydrate	Acidifying agent and buffer component	Supports pH control
Glycerin	Humectant	Reduces perceived dryness and supports skin hydration
Glyceryl stearate	Emulsifier and emollient	Helps create the cream structure
Isopropyl myristate	Emollient and penetration-supporting vehicle	Influences spreadability, absorption, and acne-user acceptability
Potassium sorbate	Preservative	Supports microbial control in the aqueous phase
Propylene glycol	Solvent and humectant	Can improve drug solubilization but may cause irritation in some users
Purified water	Continuous aqueous phase	Determines emulsion balance and microbial risk
Stearyl alcohol	Thickener and co-emulsifier	Controls rheology and application feel
Tromethamine	pH adjuster and buffering agent	Supports formulation pH and chemical stability

The commercial formulation opportunity is not simply to replace one excipient. A materially different vehicle can change drug release, skin permeation, irritation, preservative performance, rheology, and bioequivalence requirements.

Which excipients create the largest commercial opportunities?

Solvent-system optimization

Propylene glycol, benzyl alcohol, and isopropyl myristate are central to the product’s solvent and delivery system. A competing formulation could seek to reduce propylene glycol or benzyl alcohol while maintaining clascoterone solubilization.

Potential replacement systems include:

• Propylene glycol-free solvent blends
• Ethoxydiglycol-containing systems
• Transcutol-based vehicles
• Medium-chain triglycerides
• Diethylene glycol monoethyl ether systems
• Lipid-based emulsions
• Anhydrous or low-water creams

The principal commercial benefit would be improved tolerability. The development risk is that solvent changes can alter clascoterone thermodynamic activity and skin flux. A less irritating formulation could also have lower drug delivery, requiring extensive comparative testing.

Noncomedogenic emollient systems

Isopropyl myristate contributes to spreadability and emollience, but acne products must minimize concerns about greasiness and comedogenicity. Alternative emollients could include caprylic/capric triglyceride, C12-15 alkyl benzoate, dicaprylyl carbonate, or selected synthetic esters.

A replacement vehicle would need to demonstrate:

• Equivalent or acceptable clascoterone release
• No increase in comedogenicity
• Comparable or better patient usability
• Stable viscosity across temperature ranges
• No phase separation
• Compatible preservative performance

An emollient redesign is most attractive for premium dermatology positioning, especially if the product is marketed for sensitive or irritation-prone skin.

Preservative strategy

Winlevi uses benzyl alcohol and potassium sorbate in an aqueous cream. Preservative systems create an opportunity for a lower-irritation product, but they also create a substantial microbiological burden.

Potential approaches include:

• Reduced benzyl alcohol concentration
• Phenoxyethanol-based systems
• Organic-acid preservation
• Multifunctional excipients with antimicrobial activity
• Airless packaging that reduces repeated microbial ingress
• Preservative-free packaging, if stability and in-use testing support it

A preservative-free product would require a packaging system that controls contamination during repeated patient use. The regulatory burden would include antimicrobial effectiveness testing, microbial limits, in-use stability, container-closure integrity, and potentially a different product classification strategy.

Rheology and sensory performance

Cetyl alcohol, stearyl alcohol, and glyceryl stearate establish the semisolid structure. Their ratios affect:

• Extrudability from the tube
• Ease of spreading
• Residence time on skin
• Occlusiveness
• Greasiness
• Rub-in time
• Drug release
• Physical stability

A thinner cream may improve cosmetic acceptability but increase runoff or reduce residence time. A thicker cream may improve local retention but reduce adherence because patients perceive it as heavy.

This is a high-value opportunity because dermatology adherence is strongly influenced by sensory attributes. A vehicle with faster rub-in, lower residue, and reduced pilling under sunscreen or makeup could command a premium even if the active ingredient is unchanged.

What formulations could compete with Winlevi?

Lotion and emulsion systems

A lotion could improve spreadability over large acne-affected areas, including the trunk. The challenge is maintaining dose uniformity and preventing separation. A lotion may also increase the risk of runoff and accidental transfer.

Gel-cream systems

A gel-cream could offer a lighter sensory profile while retaining semisolid residence time. Carbomer, acrylates-based polymers, or cellulose derivatives could provide structure, but polymer selection can alter drug release and pH sensitivity.

Foam formulations

Foams are commercially attractive in dermatology because they spread quickly and reduce rubbing. A clascoterone foam could target scalp, chest, and back application. Foam development would require work on propellant compatibility, dose delivery, flammability controls, container pressure, and scale-up.

Spray or pump delivery

A metered pump could improve dose consistency and reduce direct finger contact. It could be suitable for truncal acne but would require control of spray pattern, droplet size, actuation force, and ocular exposure.

Wash-off products

A clascoterone cleanser could expand use among patients who do not want a leave-on product. Wash-off delivery creates a difficult exposure problem because contact time is shorter. It may require higher concentration, penetration enhancers, or a substantially different clinical development program.

Combination products

Potential combinations include clascoterone with:

• Benzoyl peroxide
• Adapalene
• Tretinoin
• Topical antibiotics
• Salicylic acid
• Antifungal or anti-inflammatory actives for adjacent dermatologic indications

Combination products could improve treatment convenience and reduce the need for multiple applications. They also create compatibility, stability, labeling, and clinical attribution issues. A combination containing an established active may be pursued through a 505(b)(2) pathway when the regulatory strategy supports reliance on existing data, but the exact pathway depends on formulation, indication, dosing, and clinical claims.[2]

What patents protect Winlevi and its formulation?

Winlevi’s protection is likely to involve several layers:

1. Clascoterone composition-of-matter rights.
2. Therapeutic-use patents covering androgen-mediated skin disorders.
3. Topical formulation patents.
4. Dosage, concentration, or administration patents.
5. Manufacturing and crystallization rights.
6. Regulatory exclusivity and Orange Book-listed patents.

The formulation itself can be protected through claims directed to excipient ranges, pH, particle size, polymorphic form, viscosity, drug release, or treatment method. A formulation patent is commercially stronger when it claims a narrow technical relationship that competitors cannot readily avoid, such as a defined solvent ratio or release profile.

The FDA approved Winlevi on August 26, 2020.[1] The product’s five-year new chemical entity exclusivity therefore ran until August 26, 2025, subject to the operation of applicable FDA submission rules. Patent expiration dates may extend beyond regulatory exclusivity and remain the principal barrier to generic entry.

The FDA Orange Book is the controlling public source for currently listed patents and pediatric exclusivity information. Patent listings can change through updates, corrections, delistings, litigation outcomes, or regulatory determinations.[3]

How strong is the patent estate for Winlevi?

The estate is strongest if it combines broad clascoterone rights with enforceable topical-use and formulation claims. The estate is weaker against a generic that can:

• Use a different cream base
• Avoid claimed excipient ranges
• Select a different concentration or pH
• Design around a specific release limitation
• Challenge validity or enforceability
• Demonstrate pharmaceutical equivalence through an alternative vehicle

Excipient patents generally provide narrower protection than composition-of-matter patents. Their value depends on whether the claims capture a necessary formulation feature or only one commercially convenient embodiment.

When does Winlevi lose exclusivity?

Winlevi’s FDA new chemical entity exclusivity began with approval in 2020 and reached its five-year endpoint in 2025.[1] That endpoint does not itself authorize generic marketing. An ANDA applicant must address applicable Orange Book patents and satisfy FDA requirements for pharmaceutical equivalence and bioequivalence.

The key entry pathways are:

Entry route	Core requirement	Commercial effect
Paragraph III ANDA certification	Generic accepts delayed entry until patent expiration	Predictable but later launch
Paragraph IV certification	Applicant asserts listed patent is invalid, unenforceable, or not infringed	Can create litigation and 180-day exclusivity issues
Authorized generic	Brand-linked generic supply	Can reduce third-party generic economics
505(b)(2) product	Relies partly on existing information but changes product or use	Supports differentiated vehicles or indications
OTC switch	Requires FDA approval of nonprescription status	Not currently established for Winlevi

Which companies are challenging Winlevi?

Public generic competition should be assessed through FDA ANDA activity, Orange Book certifications, federal court dockets, and company filings. A Paragraph IV challenge can trigger patent litigation under the Hatch-Waxman framework, with a potential 30-month stay of approval under applicable conditions.[4]

There is no biosimilar pathway for Winlevi because clascoterone is a chemically synthesized small molecule, not a biologic. Competition will come through ANDAs, 505(b)(2) products, private-label dermatology products, and alternative acne therapies.

What is the FDA regulatory status of Winlevi?

Winlevi is FDA-approved as clascoterone cream, 1%, for topical treatment of acne vulgaris in patients 12 years and older.[1] The approval does not establish approval for androgenetic alopecia, seborrheic dermatitis, or other androgen-mediated conditions.

For a new excipient system, the development route depends on the extent of change:

• An ANDA may be appropriate for a product meeting sameness and bioequivalence requirements.
• A 505(b)(2) application may be appropriate for a materially different vehicle, delivery system, strength, or indication.
• A new drug application may be required where reliance on the reference product is insufficient.

Topical products increasingly require comparative product characterization, including in vitro release testing, rheological analysis, particle or globule characterization, microscopic structure, pH, viscosity, and physical stability. The closer the formulation is to the reference product, the more credible an abbreviated development strategy becomes.[5]

What manufacturing and IP barriers affect commercial entry?

The main manufacturing barriers are:

• Consistent clascoterone assay and content uniformity
• Control of emulsion droplet size and phase structure
• Preservative distribution across phases
• Temperature-sensitive viscosity control
• Tube filling and air entrapment control
• Long-term stability under accelerated conditions
• Scale-up of homogenization and mixing
• Container compatibility and extractables testing

The active ingredient supply chain also matters. A supplier that controls a robust clascoterone synthesis, impurity profile, polymorph, or crystallization process can create a practical barrier even if the final cream is designed around a different excipient system.

Geographic opportunity exists in the United States, Europe, Japan, Canada, and selected emerging dermatology markets. Each market presents separate requirements for topical bioequivalence, excipient acceptance, labeling, patent linkage, and local manufacturing. A global formulation should avoid excipients with region-specific restrictions or different maximum-use precedents.

How does Winlevi compare with competing acne products?

Product category	Active approach	Vehicle opportunity	Competitive weakness
Winlevi	Topical androgen-receptor inhibition	Cream, lighter emulsion, foam, pump	Higher product cost and patent barriers
Benzoyl peroxide	Antibacterial and keratolytic	Wash, gel, cream	Irritation, bleaching, dryness
Topical retinoids	Comedolytic	Gel, lotion, cream, microsphere	Irritation and adherence limitations
Topical antibiotics	Antibacterial	Gel, solution, lotion	Resistance concerns and duration limits
Hormonal oral therapies	Systemic antiandrogenic effect	Oral dosage forms	Systemic exposure and safety monitoring

Winlevi’s commercial differentiation depends on preserving local activity while improving tolerability and adherence. The most defensible product strategy is a vehicle that delivers measurable patient-use benefits without creating a large regulatory or patent exposure.

What licensing deals and commercial partnerships are relevant?

Winlevi was developed by Cassiopea, now part of Cosmo Pharmaceuticals. Cosmo commercializes Winlevi in the United States and has used commercial partnerships for selected international markets and product expansion activities.[6]

Licensing value for an excipient or delivery platform would be highest where the technology offers:

• A demonstrable reduction in irritation
• Better truncal coverage
• Improved cosmetic acceptability
• A patentable formulation distinction
• Lower manufacturing cost
• Compatibility with a 505(b)(2) strategy
• A path to additional androgen-mediated indications

Excipient suppliers should prioritize formulation development agreements, regional rights, or co-development structures rather than commodity supply arrangements. The active ingredient is the primary identity of the product, but delivery technology can determine market segmentation and lifecycle value.

Key Takeaways

• Winlevi is a clascoterone 1% topical cream approved for acne vulgaris in patients 12 years and older.
• Its excipient system combines solvents, emollients, fatty alcohols, preservatives, humectants, buffering agents, and water.
• The largest formulation opportunities are lighter creams, propylene glycol-reduced systems, preservative-optimized products, foams, pumps, and combination therapies.
• Winlevi’s five-year FDA new chemical entity exclusivity began in 2020 and ended in 2025. Patent barriers may extend beyond that date.
• Generic entry will depend on Orange Book patents, ANDA certifications, topical bioequivalence, and formulation design-around options.
• No biosimilar pathway applies because clascoterone is a small-molecule drug.
• Formulation patents are commercially valuable when they claim necessary delivery characteristics rather than replaceable excipient choices.
• The strongest licensing targets are excipient and delivery platforms that improve tolerability, spreadability, truncal application, or manufacturing economics.

FAQs

Can a generic Winlevi use different excipients?

Yes. An ANDA applicant may use different inactive ingredients if the product meets applicable pharmaceutical equivalence, safety, quality, and bioequivalence requirements. The formulation change can increase development and regulatory testing requirements.

Is clascoterone suitable for a preservative-free cream?

Potentially, but a preservative-free cream would require appropriate container-closure, in-use, microbial, and stability controls. Airless pumps or unit-dose systems may be more suitable than conventional tubes.

Could clascoterone be developed as a foam?

Yes. A foam could improve spreadability and patient acceptance, particularly for truncal or scalp application. It would require new work on propellants, packaging, delivered dose, stability, and clinical performance.

Does Winlevi have biosimilar competition?

No. Biosimilars apply to biological products. Clascoterone is a chemically synthesized small molecule, so competition would arise through generic, 505(b)(2), or other small-molecule pathways.

What is the most attractive excipient opportunity for Winlevi?

A low-irritation, fast-spreading vehicle with equivalent clascoterone release and improved cosmetic performance has the clearest commercial potential. The opportunity is strongest if supported by formulation claims, patient-use data, and a credible abbreviated regulatory pathway.

References

1. U.S. Food and Drug Administration. (2020). Winlevi (clascoterone) cream, 1%: Prescribing information. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2022). Applications covered by section 505(b)(2). https://www.fda.gov
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
4. U.S. Food and Drug Administration. (2017). M30: Regulatory submissions in electronic format: General considerations. https://www.fda.gov
5. U.S. Food and Drug Administration. (2022). In vitro release test studies for topical drug products submitted in ANDAs: Guidance for industry. https://www.fda.gov
6. Cosmo Pharmaceuticals N.V. (2024). Annual report. https://www.cosmopharma.com